Quick Takeaways
- Ikarian Capital, LLC filed SCHEDULE 13G for Forte Biosciences, Inc. Common Stock, $0.001 par value (FBRX).
- Disclosed ownership: 9.5%.
- Date of event: 31 Dec 2024.
Ikarian Capital, LLC - 31 Dec 2024 SCHEDULE 13G Report for Forte Biosciences, Inc. Common Stock, $0.001 par value (FBRX)
- Filing Manager
- Ikarian Capital, LLC
- Reporting Manager
- Ikarian Capital, LLC
- Symbol
- FBRX
- Shares outstanding
- 6,412,895 shares
- Disclosed Ownership
- 609,225 shares
- Ownership
- 9.5%
- Form type
- SCHEDULE 13G
- Filing time
- 14 Feb 2025, 13:15:56 UTC
- Date of event
- 31 Dec 2024
- Next filing
- 14 Aug 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Ikarian Capital, LLC disclosed 9.5% ownership in Forte Biosciences, Inc. Common Stock, $0.001 par value (FBRX) on 31 Dec 2024."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 14 Feb 2025, 13:15.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Ikarian Capital, LLC | 9.5% | 609,225 | 0 | 609,225 | /s/ Neil Shahrestani | Neil Shahrestani, Sole Manager | |
| Neil Shahrestani | 9.5% | 609,225 | 0 | 609,225 | /s/ Neil Shahrestani | Neil Shahrestani, Sole Manager |